What if the medications changing everything about obesity treatment are also creating problems nobody saw coming? We’re living through a genuine before-and-after moment in obesity medicine. Drugs that once seemed like science fiction are now producing 20, even 25% weight loss in real patients. But the questions piling up are just as staggering as the results: What happens to your muscle? Your bone? Your sense of self? And what happens when the medication stops?

Holly and Jim sit down with Dr. Ken Fujioka, an endocrinologist, director of the Nutrition and Metabolic Research Center at Scripps Clinic, and one of the very first physicians to build an entire career around treating obesity, long before it was popular or even respected. He’s run over 100 clinical trials, treated thousands of patients a month, and watched this field go from Fen-phen clinics to GLP-1 breakthroughs. If anyone has the perspective to separate the genuine revolution from the hype, it’s Ken.

This episode is a masterclass in what actually happens in the exam room, not in a clinical trial, not in a headline, but with real patients facing real tradeoffs. Ken is refreshingly practical, deeply experienced, and not trying to win any argument. He’s just trying to help people build healthier lives in the middle of one of the fastest-moving moments medicine has ever seen.

Discussed on the episode:

Why a shortage revealed a danger nobody was talking about, and why emergency rooms are still seeing the consequences
The patients who are actually reaching their goal weight for the first time ever (and what that creates as the new problem to solve)
What Ken tells patients who want to reduce or stop their medication, and the pattern he keeps seeing a few months later.
The one group of patients he’s seen keeps the weight off without staying on the drugs, and what might explain it.
Why losing weight faster is one of the biggest mistakes being made right now, and what the bariatric surgery literature has been telling us for years
How Ken decides which medication to prescribe and why insurance coverage is always the first question
The muscle loss conversation: why it’s like pulling teeth, and the one thing he’s considering making non-negotiable
What the next generation of obesity drugs looks like, and the hormone that once seemed like a crazy idea that now has Ken most excited
His rapid-fire answers: the most underrated obesity treatment tool, the biggest mistake clinicians make, and the one thing patients should protect above everything else
The single thing Ken hopes every listener walks away remembering